Predictors of Enrolment in a Transoral Surgical Trial for HPV ‐Related Oropharyngeal Carcinoma
Clinical Otolaryngology · 2026
DOI: 10.1111/coa.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Otolaryngology, 2026. Verfasst von Nina Gallo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections, Patient Selection. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
This study evaluated demographic, clinical and perceptual factors associated with enrolment in a Phase III transoral surgical trial for HPV‐related oropharyngeal carcinoma.
Design
Single‐centre, questionnaire‐based cross‐sectional pilot study of patients screened for PATHOS trial.
Setting
Tertiary cancer centre participating in the PATHOS trial.
Participants
Patients with p16‐positive oropharyngeal carcinoma were eligible for the trial. Of 100 patients screened, 70 met trial eligibility and 51 completed a telephone questionnaire and were included. Inability to complete the questionnaire because of cognitive impairment or a language barrier was a prespecified survey exclusion criterion. However, no patient was excluded for either reason. Main Outcome Measures Primary outcome was the patient decision to enrol or decline participation in PATHOS (written consent). Predictor variables included demographic and clinical characteristics and responses to a 31‐item Likert‐scale questionnaire.
Results
Among 51 eligible patients who completed the questionnaire, 29 (57%) enroled in the trial. On univariable analysis, significant predictors included perceptions of treatment quality, toxicity, quality of life, travel distance, trial comprehension, randomisation, medical terminology, trust, prior trial experience and concern about being treated as a ‘guinea pig’. On multivariable analysis, prior trial experience ( p = 0.022) and not feeling like a ‘guinea pig’ ( p = 0.047) remained significant, with travel distance trending ( p = 0.087).
Conclusions
Trial enrolment was driven primarily by prior exposure to clinical research and perceptions of vulnerability and trust, rather than by demographic or tumour factors. Addressing fears of being a ‘guinea pig’, improving trial comprehension and mitigating travel‐related barriers may enhance accrual and promote more equitable participation in head and neck cancer trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
- Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA.
- Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- AdventHealth Medical Group, Radiation Oncology Specialists, Orlando, Florida, USA.
- AdventHealth Cancer Institute, Orlando, Florida, USA.
- University of Central Florida College of Medicine, Orlando, Florida, USA.
ORCID-Profile: Nina Gallo, Caroline Casey, Andrea Costantino, Xiang Zhu, J Scott Magnuson, Bruce H Haughey
Zitieren
APA
Gallo, N., Casey, C., Costantino, A., Kandula, S., Mekhail, T., Zhu, X., Magnuson, J. S., & Haughey, B. H. (2026). Predictors of Enrolment in a Transoral Surgical Trial for HPV ‐Related Oropharyngeal Carcinoma. Clinical Otolaryngology. https://doi.org/10.1111/coa.70160
Vancouver
Gallo N, Casey C, Costantino A, Kandula S, Mekhail T, Zhu X, et al. Predictors of Enrolment in a Transoral Surgical Trial for HPV ‐Related Oropharyngeal Carcinoma. Clinical Otolaryngology. 2026. doi:10.1111/coa.70160
BibTeX
@article{Gallo2026,
author = {Gallo, Nina and Casey, Caroline and Costantino, Andrea and Kandula, Shravan and Mekhail, Tarek and Zhu, Xiang and Magnuson, J Scott and Haughey, Bruce H},
title = {Predictors of Enrolment in a Transoral Surgical Trial for HPV ‐Related Oropharyngeal Carcinoma},
journal = {Clinical Otolaryngology},
year = {2026},
doi = {10.1111/coa.70160}
}
EUVIMED